Detail of "5304-34-7"

Reference

Pharmaceutical intervention of advanced glycation endproducts

Pharmaceutical intervention of advanced glycation endproducts.In this study， 341028-37-3 and 5304-34-7 are also used. Cerami, Anthony; Ulrich, Peter (The Kenneth S. Warren Laboratories, Tarrytown, NY 10591, USA). Novartis Foundation Symposium, 235(Aging Vulnerability), 202-216 (English) 2001 John Wiley & Sons Ltd. CODEN: NFSYF7. ISSN: 1528-2511. DOCUMENT TYPE: Journal; General Review CA Section: 1 (Pharmacology) Section cross-reference(s): 14 A review. Recent studies have revealed that reducing sugars, such as glucose, react with proteins through non-enzymic glycosylation to form irreversible, covalently crosslinked proteins known as advanced glycation endproducts (AGEs). Furthermore, it has been demonstrated that this naturally occurring process, accelerated in diabetics due to hyperglycemia, impairs biol. functions leading to cardiovascular disorders, as well as diabetic and age-related complications. Pharmaceutical intervention to prevent or reverse these complications have focused on inhibiting the formation of AGEs by compds. such as dimethyl-3-phenacylthiazolium chloride or breaking the glucose derived crosslinks by selective cleavage. Intervention targeted at AGE crosslinks in vivo offers a way to interfere with age-related changes of tissues. .